We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 901

ML Strategies Health Care Lame Duck Preview
  • Mintz
  • USA
  • November 2 2018

With the opioid bill passed, the House on recess and the Senate having cut a deal to get out the door, we all begin to wonder: after the dust settles


Federal government takes steps toward ubiquity of cannabis drugs
  • Reed Smith LLP
  • USA
  • November 1 2018

The federal government finally seems ready to acknowledge the potential advantages of medicinal CBD and marijuana-derived medication. The Food and


On Prevention of Federal Fraud on the FDA Claims That Avoid Buckman
  • Reed Smith LLP
  • USA
  • October 29 2018

Private plaintiffs love to scream “fraud on the FDA”! Agency fraud is their magic potion for dissolving any FDA action that they don’t like. Just


Washington Healthcare Update- 8 Oct, 2018
  • McGuireWoods Consulting LLC
  • USA
  • October 8 2018

D.C. obsessed with Supreme Court nomination; opioids legislation hits the president’s desk for signature; 340B continues to be of concern


ML Strategies Weekly Health Care Preview - Week of October 1, 2018
  • Mintz
  • USA
  • October 1 2018

You might have missed it but Congress averted a government shutdown last week. While several appropriations bills passed on time for the first time in


Senate Overwhelmingly Clears Bipartisan Opioid Package
  • Squire Patton Boggs
  • USA
  • September 24 2018

Nearly three months following House passage of a legislative proposal related to America’s opioid epidemic, the Senate overwhelmingly cleared its own


A Look Inside Trump's 4-Point Plan For Curbing Drug Prices
  • Ropes & Gray LLP
  • USA
  • May 18 2018

On May 11, President Donald Trump outlined his administration’s four-point plan for curbing prescription drug prices. With rare exceptions, the plan


Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • May 14 2018

On Capitol Hill, reaction to President Donald Trump’s “American Patients First” plan to bring down prescription drug prices fell predictably along


FDA signals increasing focus on cybersecurity requirements
  • Hogan Lovells
  • USA
  • April 25 2018

With the continued explosion of software and software-controlled medical devices, including the growing use of machine learning and artificial


Federal Court Dismisses CFAA Claims Against Former Executive, Allows CFAA and DTSA Claims Against Competitor in Pharmaceuticals Trade Secret Dispute
  • Seyfarth Shaw LLP
  • USA
  • April 18 2018

A recent decision from the Eastern District of Pennsylvania reinforces the importance of the timing of purported misconduct in alleged violations of